Navigation Links
BioMosaics' Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
Date:9/10/2007

BURLINGTON, Vt., Sept. 10 /PRNewswire/ -- BioMosaics Inc., a cancer biomarker development company, announced today that it has received CE marking for its proprietary products for the identification of Glypican-3 (GPC3) in human blood and in tissue as in vitro diagnostic tests. This will allow the GPC3 (Human Glypican-3) ELISA Kit for detecting GPC3 in human serum or plasma, and the GPC3 (Human Glypican-3) Monoclonal Antibody (clone 1G12) to detect GPC3 in tissue by immunohistochemistry (IHC), to be marketed in the European Union.

GPC3, an oncofetal antigen, is a member of the glypican family of glycosyl phosphatidylinositol-anchored cell-surface heparan sulfate proteoglycans. The anti-GPC3 monoclonal antibody (MAb; clone 1G12) has also been used to assess GPC3 expression in malignant and non-malignant liver tissue samples and for ELISA detection of GPC3 in the serum. Capurro et al. have shown that GPC3 is expressed at the protein level by immunohistochemistry in most cases of primary liver cancer including small tumors, but is undetectable in normal liver and benign hepatic lesions [Gastroenterology. 2003; 125:89-97]. Three recent major studies using BioMosaics GPC3 MAb have confirmed the early presence of GPC3 on hepatocellular carcinoma (HCC) and highly dysplastic cirrhotic nodules. [Wang XY et al, Human Pathology. 2006; 37(11):1435-41, Libbrecht et al, Am J Surg Pathol. 2006. 30(11):1405-1411, and Di Tommaso, Hepatology. 2007; 45(3):725-34].

Primary Liver Cancer, or Hepatocellular Carcinoma, is one of the most common and aggressive malignant tumors worldwide, causing an estimated one million deaths annually. Over 430,000 new cases of HCC are diagnosed each year. The main causative agents are hepatitis B virus (HBV), hepatitis C virus (HCV), as well as alcoholic cirrhosis and non-alcoholic steatohepatitis (NASH) which is associated with obesity, diabetes, and insulin resistance factors. The incidence of HCC has been steadily increasing over the
'/>"/>

SOURCE BioMosaics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies
2. Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
5. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
8. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
9. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
10. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
11. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BETHESDA, Md. , Sept. 16, 2014 ... a biotechnology company developing DCVax® personalized immune therapies for ... the first product to receive formal designation as a ... to Medicines Scheme" (EAMS) launched in the UK in ... a 2-step process for early access approval under the ...
(Date:9/16/2014)... Sept. 16, 2014 Imprimis Pharmaceuticals, Inc. (Nasdaq: ... to delivering high quality and novel medicines to physicians ... Executive Officer Mark Baum will be a ... Select Conference in New York City.  Mr. Baum will ... Dropless™ campaign in ophthalmology. The presentation is scheduled for ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... (PRWEB) September 16, 2014 Cloud ... Live Streaming (HLS) & UStream API’S to serve m3u8 ... wonderful feature for broadcasting live video events with hundreds ... apps. , The App Builder is known for making ... android, iOS, BlackBerry and Windows 8 and already over ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new ... with a bad heart condition. , Clients who have ... insurance if they compare quotes. Most agencies will insure ... on the actual and past medical condition. , ... heart attacks in the past, his or her chances ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) tracer is effective ... still alive, according to a case study conducted at ... at Molecular Neuroimaging (MNI) LLC in New Haven, and ... . , Specifically, the study results suggest that an ... to latch onto a protein called tau that accumulates ...
(Date:9/16/2014)... predict a man,s risk of getting prostate cancer after ... analysis of the cancer,s genetic biomarkers, reported in ... and Biomedical Innovation,s Dr Jyotsna Batra and Distinguished Professor ... large consortia of research hubs around the world, said ... in 80,000 men. , "It,s the largest analysis of ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 An experimental ... concussion-related brain disease while a person is still alive, ... School of Medicine at Mount Sinai, and at Molecular ... 16 in the journal Translational Psychiatry. , Specifically, the ... [18 F]-T807, which is designed to latch onto a ...
Breaking Medicine News(10 mins):Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:New gene research helps pinpoint prostate cancer risk 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4
... province said the SARS virus could be stopped and could ... health department, said the average daily new cases had dropped ... He gave this assurance as he was treating three foreigners, ... were infected.// ,He said the number of cases of ...
... 2003 Annual Meeting of the American Association for Cancer Research, ... means of cancer prognosis than measuring body mass index and ... the measures for detecting breast cancer are perfect, says lead ... ,But, he says that levels of leptin which signals ...
... St Mary's Hospital, Manchester, UK, has shown that family history of ... breast cancer. A survey of a group of 99 women under ... third of them had a strong history of either breast or ... cancer, 44 per cent were found to carry// mutations in the ...
... Kansas have now studied a new electrical device,that ... victims of Parkinson's disease.,This new treatment involves implanting ... of life for Parkinson's patients. This,electrical device helps ... the,signals that otherwise cause disabling tremor. The researchers ...
... long time now a lot of health experts that to ... has been advised we should,drink at least eight 8-ounce glasses ... Researchers from Center for Human Nutrition at the,University of Nebraska ... keep ourselves hydrated.// A group of 27 male volunteers were ...
... the A & A Pain Institute in St Louis, Missouri(A ... of pain), have,found that an anticonvulsant drug levetiracetam brings dramatic ... seven patients between 39 and 67 who had,severe nerve pain ... on,the nerve, analgesic drugs were not effective in relieving the ...
Cached Medicine News:
... System is a rapid, real-time thermal cycler ... samples. By automating much of the testing ... programmable, it is the fastest, easiest to ... the market. The SmartCycler delivers highly accurate ...
... The SmartCycler System is a rapid, real-time ... prepared biological samples. By automating much of ... site individually programmable, it is the fastest, ... now on the market. The SmartCycler delivers ...
... The LightCycler 2.0 System is the ... Applied Science. This new instrument offers six ... 530, 560, 610, 640, 670, and 710nm. ... cooling by air and working with glass ...
Mx3000P instrument, desktop computer, Mx3000P software package, user's manual, one Brilliant QPCR Reagent of your choice, and custom filter wheel with 4 filters chosen from: FAM/SYBR Green I, TET, HE...
Medicine Products: